Circulating tumour cells, recist and pathological response in patients with resectable colorectal liver metastases

Author(s):  
Marisa Gomez Dorronsoro
HPB ◽  
2018 ◽  
Vol 20 ◽  
pp. S354-S355
Author(s):  
D.J. Höppener ◽  
P.M.H. Nierop ◽  
P.B. Vermeulen ◽  
D.J. Grünhagen ◽  
C. Verhoef

2015 ◽  
Vol 112 (3) ◽  
pp. 556-561 ◽  
Author(s):  
Z S Lalmahomed ◽  
B Mostert ◽  
W Onstenk ◽  
J Kraan ◽  
N Ayez ◽  
...  

2007 ◽  
Vol 451 (5) ◽  
pp. 943-948 ◽  
Author(s):  
Mark M. Aloysius ◽  
Abed M. Zaitoun ◽  
Ian J. Beckingham ◽  
Keith R. Neal ◽  
Guruprasad P. Aithal ◽  
...  

HPB ◽  
2010 ◽  
Vol 12 (4) ◽  
pp. 277-284 ◽  
Author(s):  
Gabriel Chan ◽  
Mazen Hassanain ◽  
Prosanto Chaudhury ◽  
Dionisios Vrochides ◽  
Amy Neville ◽  
...  

2013 ◽  
Vol 45 ◽  
pp. S254-S255
Author(s):  
K. Dede ◽  
F. Salamon ◽  
A. Farkas ◽  
A.M. Szász ◽  
T. Mersich ◽  
...  

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4063-4063 ◽  
Author(s):  
D. A. Wicherts ◽  
R. J. Haas de ◽  
F. Levi ◽  
T. Aloia ◽  
B. Paule ◽  
...  

4063 Background: A complete clinical response (CCR) of colorectal liver metastases (CLM) following chemotherapy has been shown unrelated to the real disappearance of active tumor. By contrast, a complete pathological response (PCR) could be more clinically relevant, but has not been explored. The aim of this study was to evaluate the incidence and outcome as well as predictive factors of PCR, in patients resected from CLM after neoadjuvant chemotherapy. Methods: In our institution 791 consecutive patients with CLM underwent liver resection after neoadjuvant chemotherapy. CCR was defined as the disappearance of all lesions after chemotherapy, and PCR was defined as the total necrosis of all metastases on the resection specimen. Both were selected from a prospective database. Patients with and without PCR were compared, survivals were determined and predictive factors for PCR were analyzed using a multivariate risk model. Results: There were 0.4% CCR (3/791) and 4% PCR (31/791). Among the 31 patients with PCR, the median number of CLM was 2.0 (range 1–13) with a maximum diameter = 3 cm for most cases (73%) at diagnosis. Ten patients (32%) had extrahepatic metastases. Compared to patients without PCR, patients with PCR were younger (p< 0.05) and had a smaller maximum tumor size (p=0.007). Rate of objective response was higher (81% vs. 52%; p=0.002) and last chemotherapy regimen contained more frequently oxaliplatin than irinotecan (p=0.05). Number of chemotherapy cycles and treatment lines were not different. At multivariate analysis, 4 predictive factors of PCR were identified: age = 60 yrs, maximum size at diagnosis = 3 cm, CEA = 40 ng/ml at diagnosis and achievement of an objective response. The probability of PCR ranged from 0.2% when all were absent to 33.8% when all were present. PCR strongly impacted overall survival (OS) that was 69% and 62% at 5 and 10 years with a disease-free survival (DFS) of 42% for both. Conclusions: PCR concerns overall 4% of patients receiving neoadjuvant chemotherapy allowing for surgery, but as much as one third of those aged less than 60 years, developing response on liver metastases smaller than 3 cm, with low CEA values. Uncommon high survival rates are observed in this setting. PCR more than CCR is a reality and strongly impacts patient outcome. No significant financial relationships to disclose.


2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15027-e15027
Author(s):  
N. Bouganim ◽  
P. Kavan ◽  
M. Eid ◽  
P. Metrakos ◽  
P. Chaudhury ◽  
...  

e15027 Background: Colorectal liver metastases treated with perioperative chemotherapy were previously shown to increase progression free survival. Given the survival benefit of bevacizumab in metastatic CRC, the aim of this study was to assess the efficacy and safety of bevacizumab based chemotherapy in the perioperative setting. Methods: In this single arm prospective pilot study, patients with resectable LM eligible to receive perioperative BV and chemotherapy were included. Kaplan Meier survival analysis was used to calculate overall survival and progression free survival. Results: A total of 60 patients were recruited, 41 male, with an average age of 55. Forty-three patients had synchronous LM. All but seven patients received pre and post-operative BV-based chemotherapy (34/60 oxaliplatin based, 22/60 CPT-11 based and 4/60 CPT-11 and oxaliplatin based). All patients underwent hepatectomy 6–8 weeks post last dose of BV. Overall response rate was 80% (48/60), 4pt with stable diseaase; 10% had a complete pathological response and 27% had no evidence of disease post hepatectomy with a median follow up of 33 months.8 patients progressed prior to surgery. Overall survival (OS) rates at 12, 24, 36 and 48 months were: 100%, 86%, 74% and 66% respectively and 5 year median survival of 55%. Progression free survival (PFS) was 14 months. Subgroup analysis of the data according to the chemotherapy pts received showed that PFS in the CPT-11 and the oxaliplatin arm were 13 and 15 months respectively. Most of the adverse events recorded were associated with the post-operative period and included wound healing (8pts), infections (2pts) and thromboemblic (6pts) disease. No sudden deaths or bowel perforations were reported. Conclusions: Bevacizumab-containing chemotherapy regimens in the peri-operative setting is effective in patients with colorectal liver metastases. Our 80% response rate and 10% complete pathological response is one of the highest reported and warrants further investigation in phase III trials. [Table: see text]


Sign in / Sign up

Export Citation Format

Share Document